Equities

Synairgen PLC

SNG:LSE

Synairgen PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)7.00
  • Today's Change0.76 / 12.18%
  • Shares traded1.39k
  • 1 Year change-22.22%
  • Beta-6.6314
Data delayed at least 20 minutes, as of May 02 2024 08:16 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Synairgen PLC had revenues remain flat at 0.00, though the company grew net income from a loss of 48.66m to a smaller loss of 17.65m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-41.40%
Return on equity-48.86%
Return on investment-48.86%
More ▼

Cash flow in GBPView more

In 2022, cash reserves at Synairgen PLC fell by 17.90m. Cash Flow from Financing totalled 1.00k or -- of revenues. In addition the company used 14.29m for operations while cash used for investing totalled 3.62m.
Cash flow per share-0.0491
Price/Cash flow per share--
Book value per share0.0793
Tangible book value per share0.0788
More ▼

Balance sheet in GBPView more

Synairgen PLC appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio6.77
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.